Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens.

Journal

Current opinion in obstetrics & gynecology

ISSN: 1473-656X

Titre abrégé: Curr Opin Obstet Gynecol

Pays: England

ID NLM: 9007264

Informations de publication

Date de publication:
29 Sep 2023

Historique:

medline: 4 10 2023

pubmed: 4 10 2023

entrez: 4 10 2023

Statut: aheadofprint

Résumé

The scope of immuno-oncology in endometrial cancer has changed rapidly in the last several years, requiring up-to-date knowledge for those who treat these patients. This article will focus on molecular profiling, recent trials, and FDA approvals of targeted immuno-oncology medications in endometrial cancer. These include immune checkpoint inhibitors alone or with combination treatment. The publication of the TCGA has led to significant focus on molecular subgroupings into POLEm, MMRd, NSMP, and p53m groups. For those patients with MMRd vs. MMRp tumors, there are indications for single agent immune checkpoint inhibitors with dostarlimab or pembrolizumab. For those with MMRp tumors, the addition of lenvatinib to pembrolizumab has proven clinical benefit. The recent publication of the RUBY and NRG-GY018 trials have shown clinical benefit in both subgroups with addition of immune checkpoint inhibitor to platinum-based chemotherapy. Now there is approval for use of dostarlimab in frontline chemotherapy and maintenance for advanced stage or recurrent endometrial cancer. Several upcoming trials investigating molecular subgroups from the TCGA are eagerly anticipated.

Identifiants

DOI: 10.1097/GCO.0000000000000917 PMID: 37792525

pubmed: 37792525

doi: 10.1097/GCO.0000000000000917

pii: 00001703-990000000-00095

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics 2022. CA Cancer J Clin 2022; 72:409–436.

Chelmow D, Brooks R, Cavens A, et al. Executive summary of the Uterine Cancer Evidence Review Conference. Obstet Gynecol 2022; 139:626–643.

Brooks RA, Fleming GF, Lastra RR, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin 2019; 69:258–279.

Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol 2020; 38:3841–3850.

Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 2010; 116:1141–1149.

Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73.

Winterhoff B, Thomaier L, Mullany S, Powell MA. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol 2020; 32:76–83.

Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31:12–39.

Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162:383–394.

Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29:1180–1188.

Pećina-Šlaus N, Kafka A, Salamon I, Bukovac A. Mismatch repair pathway, genome stability and cancer. Front Mol Biosci 2020; 7:122.

Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer 2015; 15:181–194.

Li K, Luo H, Huang L, Zhu X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 2020; 20:16.

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 2020; 10:727–742.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252–264.

Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN Guidelines with the level of evidence. Cancers (Basel) 2020; 12:738.

Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509–2520.

U.S. Food and Drug Administration. Pembrolizumab approval letter M, 2017. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. [Accessed 2 August 2023]

O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study. J Clin Oncol 2022; 40:752–761.

Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book 2020; 40:1–7.

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer 2022; 10:e003777.

U.S. Food and Drug Administration. Dostarlimab approval letter A, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer. [Accessed 2 August 2023]

Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019; 154:314–322.

Tamura K, Hasegawa K, Katsumata N, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci 2019; 110:2894–2904.

Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020; 38:2981–2992.

Makker V, Aghajanian C, Cohn AL, et al. A phase Ib/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (Study 111/KEYNOTE-146): long-term efficacy and safety update. J Clin Oncol 2023; 41:974–979.

Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 2019; 14:e0212513.

U.S. Food and Drug Administration. Pembrolizumab plus lenvatinib approval letter S, 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/simultaneous-review-decisions-pembrolizumab-plus-lenvatinib-australia-canada-and-us. [Accessed 2 August 2023]

U.S. Food and Drug Administration. Pembrolizumab and lenvatinib approval J, 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-lenvima-lenvatinib-advanced. [Accessed 2 August 2023]

Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022; 386:437–448.

The ASCO Post Staff. ‘Lenvatinib/Pembrolizumab improves survival in advanced endometrial cancer in a Phase III Trial’. September 25 AA, 2023. https://ascopost.com/issues/september-25-2021-supplement-gynecologic-cancers-almanac/lenvatinibpembrolizumab-improves-survival-in-advanced-endometrial-cancer-in-a-phase-iii-trial/.

Makker V, Colombo N, Herráez AC, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the Randomized Phase III Study 309/KEYNOTE-775. J Clin Oncol 2023; 41:2904–2910.

Zammarrelli W, Espino K, Yeoshoua E, et al. EP159/#428 Real-world experience and common adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer. Int J Gynecol Cancer 2022; 32: (Suppl 3): A111–A112.

’EISAI ADDS ALL INDICATED DOSES TO LENVATINIB DOSE EXCHANGE PROGRAM AFTER RESEARCH PRESENTED AT SGO 2022 ANNUAL MEETING’ https://www.sgo.org/news/eisai-adds-all-indicated-doses-to-lenvatinib-dose-exchange-program-after-research-presented-at-sgo-2022-annual-meeting/. [Accessed 18 September 2022].

McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351:1463–1469.

Esfahani K, Roudaia L, Buhlaiga N, et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 2020; 27: (Suppl 2): S87–S97.

Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379:2108–2121.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378:2078–2092.

Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023; 388:2159–2170.

Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 2023; 388:2145–2158.

Administration USFaD. FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer. [Accessed 28 August 2023]

Tinker AV, Sabatier R, Gravina A, et al. RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. Int J Gynecol Cancer 2022; 32: (Suppl 2): A414–A1414.

Mirza MR, Coleman RL, Hanker L, et al. 820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: a phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC). Ann Oncol 2021; 32: (Supplement 5): S770–S771.

Westin SN, Moore KN, Nieuwenhuysen EV, et al. DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC). J Clin Oncol 2020; 38: (Suppl 15): TPS6108–TPS6108.

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemothera. https://www.astrazeneca-us.com/media/press-releases/2023/imfinzi-durvalumab-plus-lynparza-olaparib-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-advanced-endometrial-cancer-when-added-to-chemotherapy-05262023.html. [Accessed 14 August 2023].

Marth C, Tarnawski R, Tyulyandina A, et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer 2022; 32:93–100.

Slomovitz BM, Cibula D, Simsek T, et al. KEYNOTE-C93/GOG-3064/ENGOT-en15: a phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma. J Clin Oncol 2022; 40: (Suppl 16): TS5623–TS15623.

Ray-Coquard IL, Rubio MJ, Paoletti X, et al. Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study). J Clin Oncol 2023; 41: (Suppl 16): TS5630–TS15630.

Testing nivolumab with or without ipilimumab in deficient mismatch repair system (dMMR) recurrent endometrial carcinoma. https://classic.clinicaltrials.gov/ct2/show/NCT05112601. [Accessed 14 August 2023].

Gorp TV, Mirza MR, Lortholary A, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer. J Clin Oncol 2021; 39: (Suppl 15): TS5608–TS15608.

Consortium RR. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer 2022; 33:109–117.

van den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020; 30:2002–2007.